genomic alterations; genomic-driven therapy; metastatic tumors; molecular tumor board; next-generation sequencing (NGS); Belgium; Genomics; Humans; Medical Oncology; Neoplasms; Precision Medicine; Oncology; Cancer Research
Abstract :
[en] PRECISION is an initiative from the Belgian Society of Medical Oncology (BSMO) in collaboration with several stakeholders, encompassing four programs that aim to boost genomic and clinical knowledge with the ultimate goal to offer patients with metastatic solid tumors molecularly guided treatments. The PRECISION 1 study has led to the creation of a clinico-genomic database. The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) and GeNeo studies will increase the number of patients with advanced cancer that have comprehensive genotyping of their cancer. The PRECISION 2 project consists of investigator-initiated phase II studies aiming to provide access to a targeted drug for patients whose tumors harbor actionable mutations in case the matched drug is not available through reimbursement or clinical trials in Belgium.
Disciplines :
Oncology
Author, co-author :
Thouvenin, J; Hospices Civils de Lyon, Medical Oncology, Lyon, France, Institut Jules Bordet, Medical Oncology Clinic, Brussels, Belgium
Van Marcke, C; UCLouvain, Ottignies-Louvain-la-Neuve, Belgium
Decoster, L; UZ Brussel, Medical Oncology, Brussels, Belgium
Raicevic, G; Sciensano, Brussels, Belgium
Punie, K; KU Leuven University Hospitals Leuven, General Medical Oncology, Leuven, Belgium
Geboes, K; Division of Digestive Oncology, Department of Gastroenterology, UZ Gent, Gent, Belgium, Department of Internal Medicine and Pediatrics, UZ Gent, Gent, Belgium
Collignon, Joëlle ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Tejpar, S; KU Leuven Hospital, Leuven
Canon, J-L; Grand Hôpital de Charleroi Site Notre Dame, Service d'Oncologie-Hématologie, Charleroi, Belgium
Peeters, M; Universitair Ziekenhuis Antwerpen, Oncology, Antwerpen, Belgium
Rutten, A; GZA Ziekenhuizen Campus Sint-Vincentius, Medical Oncology, Antwerpen, Belgium
Van de Mooter, T; GZA Ziekenhuizen Campus Sint-Vincentius, Medical Oncology, Antwerpen, Belgium
Vermeij, J; ZNA Middelheim, Medical Oncology, Antwerpen, Belgium
Schrijvers, D; ZNA, Antwerpen, Belgium
Demey, W; AZ Klina, Medical Oncology, Brasschaat, Belgium
Lybaert, W; GZA Ziekenhuizen Campus Sint-Vincentius, Medical Oncology, Antwerpen, Belgium
Van Huysse, J; AZ Sint-Jan Brugge-Oostende, Pathology, Brugge, Belgium
GR, MV, EVV, and AH are employees of Sciensano. JM and MH are employees of BSMO. DVS is an employee of Belgian Foundation against Cancer. FPD reports receiving consulting fees from Roche, Pfizer, AstraZeneca, Lilly, Novartis, Amgen, Daiichi Sankyo, Pierre Fabre, and Seagen outside the submitted work. PP reports grants and personal fees from AstraZeneca, Roche, Biocartis, MSD; personal fees from Pfizer, BMS, Takeda, Novartis, and Amgen, all outside the submitted work. KP reports grants and other from MSD; grants from Sanofi; other from Astra Zeneca, Gilead Sciences, Eli Lilly, Mundi Pharma, Novartis, Pfizer, Roche, Vifor Pharma, Medscape, Seattle Genetics, Teva, Pierre Fabre, Roche, AstraZeneca, PharmaMar, outside the submitted work; and is also the board member of the Belgian Society for Medical Oncology. KBMC reports other from Astra Zeneca, outside the submitted work. SR is the President of the BSMO. BM reports nonfinancial support and other from Illumina, during the conduct of the study; personal fees from AstraZeneca, Novartis, and Pfizer, outside the submitted work. LD reports grants from Roche, Boehringer Ingelheim, AstraZeneca, Kom op tegen Kanker, during the conduct of the study; and also grants from MSD, Roche, Astra Zeneca, BMS, outside the submitted work. CVM reports grants from BSMO, during the conduct of the study; grants from Amgen, AstraZeneca, Eli Lilly, Mundipharma, Novartis, Pfizer, Roche, Seagen, Teva, outside the submitted work. PA reports personal fees from Boehringer Ingelheim, MacroGenics, amcure, Synthon, Servier, G1 Therapeutics, Roche, Novartis, Amgen, Radius, Deloitte, Menarini, and Gilead, outside the submitted work; nonfinancial support from MSD, Roche, Pfizer, Amgen. All other authors have declared no conflicts of interest.This work was supported by grants from the 1 study and grants from the Belgian Foundation against Cancer and Kom op Tegen Kanker to the PRECISION 1 and 2 studies and the Biltema Foundation (no grant number). GeNeo is funded by a grant from Roche (no grant number). BALLETT is funded by grants from Illumina and OncoDNA (no grant number).
Zehir, A., Benayed, R., Shah, R.H., et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23 (2017), 703–713.
Bedard, P.L., Hyman, D.M., Davids, M.S., Siu, L.L., Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet 395 (2020), 1078–1088.
Massard, C., Michiels, S., Ferté, C., et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov 7 (2017), 586–595.
Mackley, M.P., Fernandez, N.R., Fletcher, B., Woolcott, C.G., Fernandez, C.V., Revisiting risk and benefit in early oncology trials in the era of precision medicine: a systematic review and meta-analysis of phase I trials of targeted single-agent anticancer therapies. JCO Precis Oncol 5 (2021), 17–26.
Schwaederle, M., Zhao, M., Lee, J.J., et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol 33 (2015), 3817–3825.
Chang, M.T., Bhattarai, T.S., Schram, A.M., et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov 8 (2018), 174–183.
Chakravarty, D., Gao, J., Phillips, S.M., et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol, 2017, 2017.
Adashek, J.J., Subbiah, V., Kurzrock, R., From Tissue-Agnostic to N-of-One therapies: (R)Evolution of the precision paradigm. Trends Cancer 7 (2021), 15–28.
André, F., Clinical utility of molecular tumor profiling: results from the randomized trial SAFIR02-BREAST. Available at https://www.abstractsonline.com/pp8/#!/10462/presentation/2168. (Accessed 14 June 2022)
Carneiro, A., Amaral, T.M.S., Brandao, M., et al. Disparities in access to oncology clinical trials in Europe in the period 2009-2019. Ann Oncol 31:suppl 4 (2020), S1142–S1215.
Van Valckenborgh, E., Hébrant, A., Antoniou, A., et al. Roadbook for the implementation of next-generation sequencing in clinical practice in oncology and hemato-oncology in Belgium. Arch Public Health, 76, 2018, 49.
Hébrant, A., Froyen, G., Maes, B., et al. The Belgian next generation sequencing guidelines for haematological and solid tumours. Belg J Med Oncol 11:2 (2017), 56–67.
Rothwell, D.G., Ayub, M., Cook, N., et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med 25 (2019), 738–743.
Gatta, G., van der Zwan, J.M., Casali, P.G., et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 47 (2011), 2493–2511.
Decoster, L., Cappoen, N., Aftimos, P.G., et al. An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: a precision trial of the Belgian society of medical oncology. J Clin Oncol, 36, 2018 TPS2615-TPS2615.
Ning, J., Wu, Q., Liu, Z., Wang, J., Lin, X., Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer. J Recept Signal Transduct Res 36 (2016), 37–44.
Bengtsson, A., Andersson, R., Ansari, D., The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci Rep, 10, 2020, 16425.
Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell 32 (2017), 185–203.e13.
Park, R., Al-Jumayli, M., Miller, K., Saeed, A., Saeed, A., Exceptional response to erlotinib monotherapy in EGFR exon 19-deleted, KRAS wild-type, chemo-refractory advanced pancreatic adenocarcinoma. Cancer Treat Res Commun, 27, 2021, 100342.
Moore, M.J., Goldstein, D., Hamm, J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007), 1960–1966.
Bailey, M.H., Tokheim, C., Porta-Pardo, E., et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173 (2018), 371–385.e18.
Radonic, T., Geurts-Giele, W.R.R., Samsom, K.G., et al. RET fluorescence in situ hybridization analysis is a sensitive but highly unspecific screening method for RET fusions in lung cancer. J Thorac Oncol 16 (2021), 798–806.
de Moor, J.S., Gray, S.W., Mitchell, S.A., Klabunde, C.N., Freedman, A.N., Oncologist confidence in genomic testing and implications for using multimarker tumor panel tests in practice. JCO Precis Oncol 4 (2020), 620–631.
Dittrich, C., Kosty, M., Jezdic, S., et al. ESMO/ASCO recommendations for a global curriculum in medical oncology edition 2016. ESMO Open, 1, 2016, e000097.
Sharma, V., Fong, A., Beckman, R.A., et al. Eye-tracking study to enhance usability of molecular diagnostics reports in cancer precision medicine. JCO Precis Oncol 2 (2018), 1–11.
Kato, S., Kim, K.H., Lim, H.J., et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-one strategy. Nat Commun, 11, 2020, 4965.
Pishvaian, M.J., Blais, E.M., Bender, R.J., et al. A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. JAMIA Open 2 (2019), 505–515.
AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an International Consortium. Cancer Discov 7 (2017), 818–831.
Mateo, J., Chakravarty, D., Dienstmann, R., et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 29 (2018), 1895–1902.
Antoniou, A., Ghislain, V., Dekairelle, A.-F., et al. Expertise ET Prestations De Services Qualite Des Laboratoires Comite Des Experts AD HOC. Available at https://www.wiv-isp.be/qml/activities/NGS/_fr/Rapport%20global%20d%C3%A9finitif%20NGS%20EEQ%202021-1%20FR.pdf. (Accessed 14 June 2022)
